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ABSTRACT  
PEGylated polylysine dendrimers are attractive and well tolerated inhalable drug delivery 
platforms that have the potential to control the release, absorption kinetics and lung retention 
time of conjugated drugs. The clinical application of these systems though, would likely 
require partial substitution of surface PEG groups with drug molecules that are anticipated to 
alter their lung clearance kinetics and clearance pathways. In the current study, we therefore 
evaluated the impact of increased surface hydrophobicity via substitution of  50% surface 
PEG groups with a model hydrophobic drug (α-carboxyl OtButylated methotrexate) on the 
lung clearance of a Generation 5 PEGylated polylysine dendrimer in rats. SENTENCE 
REMOVED. PEG substitution with OtBu-methotrexate accelerated lung clearance of the 
dendrimer by increasing polylysine scaffold catabolism, improving systemic absorption of 
the intact dendrimer and low molecular weight products of scaffold catabolism, and 
enhancing mucociliary clearance. These results suggest that the conjugation of hydrophobic 
drug on the surface of a PEGylated dendrimer is likely to accelerate lung clearance when 
compared to a fully PEGylated dendrimer. 
KEYWORDS 
Dendrimer, Pulmonary, Drug delivery, Clearance, Inhalation 
NON-STANDARD ABBREVIATIONS 
Polyethylene glycol (PEG), Bronchoalveolar lavage fluid (BALF), size exclusion 
chromatography (SEC), Lipopolysaccharide (LPS), Phosphate buffered saline (PBS), Bovine 
serum albumin (BSA) 
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1. INTRODUCTION 
In recent years, inhaled drug delivery has attracted increasing interest by the pharmaceutical 
industry and at present, several inhalable drug delivery systems (liposomes) are in advanced 
stages of clinical trials [1]. The inhaled administration of drugs results in high local 
concentrations in the lung tissue, lung lining fluid and in lung-resident immune cells. This 
facilitates the improved and site directed treatment of lung specific diseases such as chronic 
obstructive lung disorders, asthma, cystic fibrosis, lung infections and lung cancer [2].  The  
inhaled route can also provide a non-invasive means to deliver non-orally available drugs to 
the systemic circulation by virtue of the large absorptive surface area (70 – 140 m2 in adult 
human lungs), thin alveolar epithelium (0.1−0.2 μm), rich blood supply, relatively low 
enzymatic activity compared with the gastrointestinal tract and liver, and avoidance of 
hepatic and intestinal first-pass drug metabolism, [3]. Due to these attributes, the rate of 
absorption of small molecule drugs is rapid across the pulmonary epithelium in comparison 
to larger molecules such as proteins [3].  
Immediate drug action in the lungs through the inhaled delivery of simple small molecule 
solutions or dry powders is beneficial in some cases (e.g. when treating an asthma attack with 
bronchodilators). In other instances, sustained exposure of the lungs to drugs is a better 
approach to limit lung related drug toxicity and promote a more prolonged duration of 
activity (eg. when treating lung cancers or lung infections with highly toxic drugs).  To this 
end, the systemic absorption of macromolecules and nanoparticles from the lungs is limited 
which promotes more prolonged lung exposure. There is therefore increasing interest in the 
development of inhalable ‘nanomedicines’ or drug delivery systems based on biocompatible 
nanosized colloids, polymers or particles that are covalently or non-covalently loaded with 
lung-active drugs. These systems can be designed to display semi-tuneable rates of drug 
liberation in the lungs, cell targeting, biodegradation/bioerosion and in some cases, systemic 
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access [4, 5]. Following on from the clinical success of injectable liposome-based 
nanomedicines, a number of inhalable liposomal nanomedicines (>100 nm in diameter) have 
also been investigated and are now in various stages of human clinical trials [6] . 
In recent years, dendrimers have also shown considerable potential as structurally refined, 
sub-nanometer sized drug delivery vehicles in several pre-clinical studies [7-9] and an 
injectable chemotherapeutic dendrimer is currently in Phase I clinical trials in Australia for 
the treatment of advanced breast cancer (DEP-docetaxel; Starpharma Pty Ltd). PEGylated 
polylysine dendrimers have also been explored as potential inhalable drug delivery vehicles 
that exhibit controlled drug release and tuneable lung absorption kinetics, lung retention 
times and rates of biodegradation [9-11]. The lung clearance kinetics of fully PEGylated 
polylysine dendrimers of various sizes has recently been well described in rats, and a 
comparison has been made between the kinetics of a fully PEGylated dendrimer and a 
dendrimer where 50% of the surface PEG groups were substituted with the relatively 
hydrophilic drug doxorubicin [9, 11]. In general, the 56 kDa doxorubicin conjugated 
dendrimer was rapidly (60%) cleared from the lungs in the first 24 h, but thereafter showed 
slower lung clearance, with equal proportions of the dendrimer recovered in the 
bronchoalveolar lavage fluid (BALF) and lung tissue over 7 days. Around 13% of the 
dendrimer dose was absorbed from the lungs as the intact construct. This was in contract to a 
78 kDa fully PEGylated dendrimer which showed only 2% bioavailability and was 
extensively cleared from the lungs via the mucociliary escalator, such that after 7 days almost 
the entire dendrimer dose remaining in the lungs was associated with the lung tissue (rather 
than BALF) [9].  To this point however, it is not known what effect increasing surface 
hydrophobicity will have on lung clearance kinetics and pathways, for instance, following the 
substitution of 50% surface PEG chains with more hydrophobic drugs. Nanoparticles with 
hydrophobic surfaces however, have been found to form stable polyvalent bonds with mucin 
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that promotes their entrapment in airway mucus and clearance via mucociliary expulsion 
when compared to more hydrophilic particles that have better mucus penetrating properties 
[12]. 
In the current study, we therefore sought to examine the hypothesis that replacing 50% of 
surface PEG moieties on a dendrimer with hydrophobic drug accelerates lung clearance when 
compared to a fully PEGylated construct. This hypothesis was tested by comparing the lung 
clearance kinetics and mechanisms of a fully PEGylated (PEG1100) Generation 5 polylysine 
dendrimer to one where 50% of the surface PEG groups were substituted with a model 
hydrophobic drug (α-carboxyl OtButyl-methotrexate; MTX) in rats [13]. Hydrophobic 
particles can also interact more strongly with proteins and cell surfaces than hydrophilic or 
highly PEGylated systems, and thereby potentially enhance the particles immunogenicity. 
The presence of lung inflammation has also been reported to increase the systemic absorption 
of macromolecules from the lungs and reduce mucociliary clearance and the phagocytic 
activity of alveolar macrophages [14-17]. We therefore also evaluated whether the more 
hydrophobic MTX dendrimer promoted localised lung inflammation after inhaled delivery, 
which could have an impact on lung clearance kinetics and pathways, and alter interpretation 
of the results. 
  
  
7 
 
2. METHODS 
2.1 Material 
Polyethylene (0.96 mm×0.58 mm) and polyvinyl cannulas (1.5 mm×2.7 mm) were purchased 
from Microtube Extrusions (NSW, Australia). Soluene, IRGA-Safe Plus, and scintillation 
vials were obtained from Perkin-Elmer, Inc. (MA, USA). Hydrogen peroxide (30% w/v) was 
purchased from Science Supply (VIC, Australia). Saline was obtained from Baxter 
International Inc. (NSW, Australia) and Marcain® and heparin were purchased from Clifford 
Hallam Healthcare (VIC, Australia). Lipopolysaccharide (LPS) from Escherichia coli was 
purchased from Sigma Aldrich (Australia). Tali® cell analysis slides and BD trucount tubes 
were from Thermo-Fisher scientific (VIC, Australia) and BD Biosciences (NSW, Australia), 
respectively. Mouse anti-rat CD32 Fc receptor block, Allophycocyanin (APC) mouse anti-rat 
CD3 and R-phycoerythrin (PE) mouse anti-rat granulocyte antibodies were obtained from BD 
Pharmingen (NSW, Australia). Rabbit anti mouse/rat F4/80 antibody was purchased from 
Abcam (VIC, Australia). Santa Cruz Biotech goat anti-rabbit IgG F(ab’)2-PE-Cy7 was 
obtained from Thermo-Fisher Scientific (VIC, Australia). Live/dead fixable violet dead cell 
marker was purchased from Life technologies (VIC, Australia). Monocyte Chemoattractant 
Protein-1 (MCP-1), tumor necrosis factor alpha (TNFα) and Interleukin 1 beta (IL1β) rat 
ELISA kits were obtained from Thermo-Fisher Scientific (VIC, Australia). Pall laboratory 
Acrodisc® syringe filters (with Mustang® E membrane) were purchased from VWR 
international (QLD, Australia). All other reagents were AR grade and were used without 
further purification  
2.2 Dendrimers  
A fully PEGylated (1100 Da linear PEG) 
3
H-labelled Generation 5 polylysine dendrimer 
[PEG dendrimer, MW 74.7 kDa (Figure 1)] was synthesized and characterized as described 
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in the Supporting Information. The synthesis and characterization of the Generation 5 
dendrimer conjugated with PEG1100 on surface ε -amino acid groups, and α-carboxyl OtBu-
methotrexate linked via a hexapeptide (PVGLIG) linker [MTX dendrimer, MW 70.9 kDa, 
(Figure 1)] on surface α-amino acid groups was described previously (Figure 1) [18]. In all 
cases, the dendrimers were radiolabelled via the incorporation of 
3
H-lysine into the 
penultimate lysine layer. The dendrimers were provided as lyophilised powders and were 
resolubilised in sterile saline to give 10 mg/ml solutions (at approx. 0.5 µCi/mg) which were 
then filtered through Acrodisc® syringe filters with Mustang® E membrane into washed and 
sterilised eppendorf tubes to remove LPS.  The solutions were stored at 4
o
C prior to use and 
were used within one month. 
2.3 Animals 
Male Sprague−Dawley rats (240−260 g) were supplied by Monash Animal Services (VIC, 
Australia) and all animal experiments were carried out with approval from the Monash 
Institute of Pharmaceutical Sciences Animal Ethics Committee. Rats were housed in a 
temperature controlled environment (21-22°C) on a 12h light/dark cycle and provided water 
at all times. With the exception of fasting animals after surgery and for 8 h after dosing, rats 
were provided free access to food at all times.  
2.4 Plasma pharmacokinetics, biodistribution and lung clearance of inhaled dendrimers 
The plasma pharmacokinetics, 7 day organ biodistribution and proportion of the dose 
excreted in urine and faeces over 7 days was evaluated in 3 groups of rats: Group 1 – 
Intravenous (IV) dosed animals; group 2 – pulmonary dosed animals; group 3 – orally dosed 
animals. Rats in these groups were cannulated via the right carotid artery as previously 
described to allow serial blood sampling and were housed in individual rat metabolism cages 
after surgical implantation of cannulas [19]. Rats in group 1 were also cannulated via the 
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right jugular vein to facilitate delivery of the IV dose. Rats were allowed to recover overnight 
form surgery prior to dosing the following day. Preliminary urine, faeces and blood (200 μl) 
samples were collected from each rat prior to dosing to provide background correction during 
liquid scintillation counting. Rats were then dosed with 5 mg/kg dendrimer in sterile saline as 
follows: 
Group 1 (IV dosed) – Rats were delivered the dendrimer dose as a 2 min IV infusion in 1 ml 
sterile saline via the jugular vein cannula, followed by the additional infusion of 0.3 ml saline 
to flush the dose remaining in the cannula into the rat. A t0 blood sample (200 μl) was then 
collected from the carotid artery cannula immediately after the completion of dosing. 
Group 2 (pulmonary dosed) -  Rats were anaesthetized under isoflurane and suspended via 
their front incisors on a dosing board held on a 30° angle as previously described [10]. The 
dendrimer dose (in 125 μl saline) was then delivered intratracheally using a PennCentury 
aerosol microsprayer (PennCentury, PA, USA; 16–22 μm particle size) to exposure the entire 
lungs to dendrimer as previously described and returned to their metabolism cages [10]. A t0 
blood sample (200 μl) was then collected from the carotid artery cannula immediately after 
the completion of dosing. 
Group 3 (orally dosed) – Since a large proportion of a pulmonary dose of nanoparticle is 
cleared from the lungs via the mucociliary escalator (and eliminated via the faeces), it was 
necessary to evaluate whether an oral dose of dendrimer is bioavailable. Fully PEGylated 
dendrimers were previously shown to not be systemically absorbed in rats after oral dosing 
[11], although this similarly needed to be evaluated for the MTX dendrimer. Thus, rats were 
anaesthetized under isoflurane and delivered an oral dose of MTX dendrimer in 1 ml saline 
via oral gavage and returned to their metabolism cages. A t0 blood sample (200 μl) was then 
collected from the carotid artery cannula immediately after the completion of dosing. 
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Further blood samples (200 μL) were collected from rats in group 1 and 2 at 0.5 h, 1 h, 2 h, 4 
h, 6 h, 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h and 168 h post dose, with the exception of rats 
delivered an IV dose of the MTX dendrimer, where pharmacokinetics were previously 
evaluated only out to 5 days post dose (and reproduced here)[8]. Immediately after the last 
blood sample was taken from IV and pulmonary dosed rats, animals were euthanised and 
major organs collected for biodistribution analysis. Rats in group 3 were sampled only out to 
3 days due to the short gastrointestinal transit time of rodents. Each day, the total volume of 
urine was recorded and an aliquot was collected for analysis. Total faeces excreted over the 7 
day post dose period were also collected and pooled for biodistribution analysis. 
All blood samples were centrifuged at 3500 rpm for 5 min to isolate plasma. A 100 µl aliquot 
of plasma was mixed with 1 ml IrgaSafe Plus™ scintillation fluid prior to determination of 
radiolabel content via liquid scintillation counting on a Packard Tri- Carb 2000CA liquid 
scintillation analyser (Meriden, CT). Similarly, 200 µl aliquots of urine were mixed with 1 ml 
IrgaSafe Plus™ and analysed via liquid scintillation counting.  
All rats used in this study were euthanized under isoflurane anaesthesia via exsanguination 
through the carotid artery cannula. For pulmonary dosed rats, the trachea was surgically 
exposed and a 5 cm length of polyethylene tubing (1.70 mm × 1.20 mm) inserted into the 
trachea to collect branchoalveolar lavage fluid (BALF) as previously described [11]. Here, 
the lungs were flushed with 4 x 5 ml volumes of wash buffer (50 mM PBS containing 0.1 
mM EDTA and 0.1% BSA).  The first two and the last two washes were separately pooled in 
pre-weighed 50 ml falcon tubes over ice. This was to allow quantification of inflammatory 
cytokines in the first 2 washes (which would be diluted too far to allow quantification in all 4 
washes), and analysis of the proportion of dendrimer remaining in the BALF and differential 
cell counting in all 4 washes. Once all the BALF samples were collected, the tubes were 
weighed to determine the mass of BALF collected.  The BALF was then centrifuged at 350xg 
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for 5 min at 4
 o
C to pellet cells and a 500-1000 μl aliquot of each BALF supernatant fraction 
was added to a 6 ml scintillation vial containing 2-4 ml IrgaSafe Plus™ to quantify the 
proportion of the pulmonary dose remaining in the BALF. BALF supernatant from the first 2 
flushes was then frozen in aliquots for later quantification of cytokines via ELISA. Cell 
pellets from all 4 washes were pooled, resuspended in 1.5 ml wash buffer and counted on a 
Tali cell counter before being analysed for the total number of alveolar macrophages, T-
lymphocytes and neutrophils as described below. The lung tissue, liver spleen and kidneys 
were also collected, weighed and frozen for later quantification of 
3
H biodistribution. 
 In a separate cohort of rats, animals were dosed with dendrimers via the lungs as described 
above (n = 3 rats) and sacrificed as described above 15 mins, 3 days or 14 days after dosing 
to evaluate the rate of dendrimer clearance from the lungs and quantify cytokine levels and 
differential cell counts in the BALF as described above. Two separate groups of rats (n = 3 
per group) were also dosed with LPS (5 mg/kg) or sterile saline via the lungs to provide 
positive and negative controls for lung inflammation. Rats in these groups were euthanised 4 
h after LPS or 7 days after saline administration.  
2.5 Biodistribution of 
3
H-dendrimers in major organs and faeces
 
 
In order to understand the fate of 
3
H dendrimers following pulmonary, IV and oral delivery 
the distribution of the 
3
H dose in the lung tissue, liver, kidneys, spleen and faeces was 
determined via liquid scintillation counting as previously described [19, 20]. Briefly, organs 
were homogenised in water and pooled faeces were initially solubilised in water (to create a 
slurry) and then later dried to create homogenous dry faeces. Samples of tissue (30-100 mg) 
or faeces (20 mg) were then solubilised in 1:1 Soluene:isopropanol as described previously 
[19, 20], bleached and then mixed with IRGASafe (10 ml). The samples were kept in the dark 
at 4°C for 3-4 days before scintillation counting to quantify organ biodistribution and the 
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proportion of the 
3
H dose excreted via the faeces (after pulmonary dosing, as a quantitative 
indicator of lung clearance via the mucociliary escalator). Background correction was 
provided by samples of blank faeces collected from each rat prior to dosing or blank organs 
obtained from untreated rats as previously described [19, 20]. 
2.6 Speciation of 
3
H Radiolabel in urine and homogenized lung tissue supernatant. 
To identify the nature of 
3
H species quantified in the plasma, urine, BALF and lung tissue 
homogenate supernatant, samples were analysed via size exclusion chromatography (SEC) 
followed by post column fraction collection.  Samples (125 μL) were centrifuged at 10,000xg 
for 1 min followed by filtration through Ultrafree®-MC 22 μm centrifuge filters (Merck 
Millipore, HE, Germany) to remove particulate material. Sample aliquots were then injected 
onto a Superdex 200 10/300 GL size exclusion column (GE Healthcare, NSW, Australia)  
and eluted at 0.5 ml/min in PBS (pH 7.4) containing 0.15 M NaCl using a Waters 590 pump 
(Millipore Corporation, Milford, MA). The column eluate was collected into 6 ml 
scintillation vials at 1 min intervals using a Gilson FC 203B Fraction Collector (Gilson Inc., 
WI, USA). Fractions were then vortex-mixed with IrgaSafe Plus™ (1 ml) and analysed for 
3
H content via liquid scintillation counting.  
2.7 Quantification of differential cell counts in BALF via flow cytometry 
Following determination of total cell count, the population of alveolar macrophages, 
neutrophils and T-lymphocytes were determined by multicolour flow cytometry analysis 
(FACS) on a BD FACSCanto™ II cell analyser (BD Biosciences, Mountain View, CA, 
USA). Aliquots containing 1 x 10
6 
cells from each rat [suspended in 150 µl of FACS buffer 
(1x PBS containing 1% BSA, 2 mM EDTA, pH 7.4)] were used to prepare samples for FACS 
analysis. The remaining cells were used to prepare control samples for each stain used for 
FACS analysis. Firstly, each sample was incubated with 1.5 µl of anti-rat CD32 Fc receptor 
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block (0.5 mg/ml) for 5 min on ice. Samples were then stained with primary antibodies (1.5 
µl monoclonal APC mouse anti-rat CD3 [0.2 mg/ml], 2 µl monoclonal PE mouse anti-rat 
granulocytes [0.2 mg/ml] and 2.5 µl polyclonal rabbit anti mouse/rat F4/80 Ab [1 mg/ml] and 
incubated for 30 min at room temperature in the dark. After 30 min, samples were diluted 
with 1 ml FACS buffer, centrifuged at 350xg for 5 min at 4 
o
C and re-suspended in 150 µl of 
FACS buffer. Samples were then incubated with secondary antibody (2.5 µl goat anti-rabbit 
IgG F(ab’)2-PE-Cy7 [0.4 mg/ml]) for 30 min at room temperature in the dark and then washed 
as described above. Finally, samples were stained with 1.5 µl violet live/dead fixable violet 
dead cell stain for 30 min at room temperature in the dark. Control samples for the three 
antibodies and live/dead stain were prepared using the single antibody and/or live/dead cell 
stain separately. After staining, all samples were incubated with 150 µl formaldehyde (4% 
v/v) for 30 min at 4
 o
C to fix the cells. Samples were then suspended in 150 µl FACS buffer 
in BD trucount tubes and stored at 4 
o
C until FACS analysis (within 3 days).  
2.8 Quantification of inflammatory cytokines in the BALF via ELISA 
The levels of TNF-α, IL-1β and MCP-1 in the first two washes of BALF were quantified 
using commercially available ELISA kits. The assays utilized a standard, 96 well quantitative 
immunometric ‘sandwich’ enzyme technique and were used according to the manufacturer’s 
recommended protocol.  BALF samples were diluted at least 2.5 times using the kit’s 
calibrator diluent. The concentration of TNF-α, IL-1β and MCP-1 in each sample was 
determined by comparing optical density readings against a standard curve generated using 
the standards provided with the kits. 
2.9 Pharmacokinetic calculations and statistics 
The concentration of each dendrimer in plasma was determined by converting the radiolabel 
disintegrations per minute to ng/mL using the specific activity of each dendrimer, assuming 
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that all 
3
H was associated with the intact dendrimer (which is not always the case and 
therefore has to be evaluated along with SEC profiles). This approach has been used 
successfully in the past to quantify the pharmacokinetics of polylysine dendrimers and enable 
an evaluation of their catabolism and 
3
H-lysine redistribution [9-11, 19]. Terminal 
(elimination) rate constants (k) were determined by regression analysis of individual 
elimination phases in the plasma concentration−time profiles. The area under the plasma 
concentration−time curves (AUC0−last) were calculated using the trapezoidal method. The 
extrapolated area under the plasma concentration-time profiles (AUCtlast−∞) was calculated by 
dividing the last measured plasma concentration by k. Plasma half-lives (t1/2) were calculated 
as 0.693/k. The absorbed fraction (Fabs) was determined by dividing the AUC after pulmonary 
delivery with the AUC after IV delivery as described previously [11]. Maximal plasma 
concentrations (Cmax) and time to peak plasma concentration (Tmax) after pulmonary dosing 
were determined by reading directly from the profiles. Statistical differences between 
pharmacokinetic parameters for IV and pulmonary dosed animals, and between organ levels 
of 
3
H dendrimer were calculated via unpaired Student's T-test. Statistical differences in 
BALF cell count and cytokine levels between groups were calculated via one way ANOVA 
with Tukey's test for least significant differences. Significance was determined at a level of p 
< 0.05. 
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3. RESULTS  
3.1 Comparison of the IV and pulmonary plasma pharmacokinetics of PEG and MTX 
dendrimers 
The dose normalized (5 mg/kg) plasma concentration-time profiles of the PEG and MTX 
dendrimers following pulmonary and IV delivery are shown in Figure 2. The IV 
pharmacokinetics of the MTX dendrimer was previously reported and is reproduced here for 
comparison [8]. In general, the MTX dendrimer was cleared more rapidly than the PEG 
dendrimer after IV administration and the terminal half-life was approx. 2.5 fold shorter than 
the PEG dendrimer (p < 0.05), despite both dendrimers having similar molecular weight. 
Over 3 fold more radioactivity associated with the MTX dendrimer (approx. 14% of the 
3
H-
dose, p < 0.05) was eliminated via the urine compared to the PEG dendrimer (approx. 4% of 
the 
3
H-dose; Table 1). 
The systemic availability for both dendrimers was limited after pulmonary administration 
(with ≤ 3% of the dose absorbed over 7 days), with peak plasma concentrations (Cmax) 
reaching 543 ± 34 ng/ml and 827 ± 202 ng/ml for the PEG and MTX dendrimers respectively 
(Table 1). Despite this, the 7 day bioavailability of the MTX dendrimer was higher when 
compared to the PEG dendrimer, and appeared to be absorbed slower from the lungs (with an 
approx. 2 fold higher Tmax compared to the PEG dendrimer) although this was not statistically 
significant as a result of the large variance in the Tmax data). The area under the plasma 
concentration-time curve for the MTX dendrimer could not be extrapolated to infinity, 
however, due to the lack of a clear elimination phase over 7 days post dose (Figure 2). 
Absolute pulmonary bioavailability could therefore not be determined for this dendrimer. 
Similar to the 
3
H elimination profile after IV delivery, a significantly larger proportion of the 
lung administered dose of the MTX dendrimer was eliminated via the urine compared to the 
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PEG dendrimer (p < 0.05). In both cases, the proportion of the urinary excreted radiolabel 
was approx. half of what was excreted following IV delivery. Taken together with the low 
pulmonary bioavailability, this suggests that some degree of breakdown of the dendrimer 
scaffold occurred in the lungs and that these 
3
H-labelled fragments were ultimately absorbed 
from the lungs and eliminated via the urine (Table 1).  
In order to confirm that mucociliary clearance of the dendrimers from the lungs into the 
gastrointestinal tract did not contribute to plasma levels of 
3
H after pulmonary administration, 
the plasma pharmacokinetics of orally administered MTX dendrimer was evaluated. This was 
previously examined for fully PEGylated polylysine dendrimers by Ryan et al, who showed 
no systemic availability of orally dosed 
3
H-label [11]. Similar to the Ryan study, the  levels of 
3
H in plasma over 72 h after oral delivery of the MTX dendrimer were below the limit of 
quantitation, confirming that plasma 
3
H detected after pulmonary administration of these 
dendrimers was entirely due to absorption from the lungs (see Supporting Information).  
Further, approx. 90% of the orally administered dose was recovered in the faeces, with less 
than 2% recovered in the liver and little in other organs (Supporting Information). 
3.2 Speciation of 
3
H-label in urine and plasma after pulmonary administration 
Plasma levels of 
3
H were too low to usefully identify the nature of 
3
H species present in the 
plasma after pulmonary administration via SEC. However, the levels of 
3
H in urine were 
generally sufficient to allow SEC analysis and to quantify the relative proportion of intact 
dendrimer and low molecular weight radiolabeled products of scaffold catabolism excreted at 
different time points post-dose. Since low molecular weight products formed after the 
catabolism of the polylysine scaffold are rapidly excreted in the urine, the SEC profiles of 
urine are unlikely to provide a useful indication of the 
3
H species present in plasma [11] .  
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The SEC profiles of urine samples collected at various times for both dendrimers showed 
mostly (where counts allowed) low molecular weight breakdown products, confirming that 
dendrimer catabolism occurred in the lungs and that the low molecular weight fragments 
were subsequently excreted via the urine (Figures 3C & D). No clear peaks representing 
intact dendrimer were present in any urine samples, as expected based on their high 
molecular weight which is above the renal elimination threshold of approx. 20-30 kDa (for 
PEGylated dendrimers) [20].  
3.3. Pulmonary retention and speciation of 
3
H-dendrimers in the lungs 
In order to understand the retention time and stability of the two dendrimers within the lungs 
after pulmonary administration, lung tissue and BALF were analyzed for 
3
H dendrimer 30 
mins and at 3, 7 and 14 days after dosing. Figure 4 shows the proportion of the administered 
dose recovered in the BALF and lung tissues at each time point. Within 30 mins post dose 
only approx. 50% of the administered dose was collectively recovered in the BALF and lung 
tissue for both dendrimers (Figure 4B & 4C). These findings are consistent with the results of 
a previous study that showed recovery of up to approx. 60% of an inhaled dendrimer dose 
within 1 h of administration using the PennCentury device, likely due to the exhalation of up 
to half of the aerosol dose during administration [10]. This is consistent with the behaviour of 
liquid aerosols during dynamic breathing in small animals. To confirm that this proportion of 
the pulmonary dose was exhaled, and was not simply expelled from the lungs and swallowed 
immediately after dosing, faeces were separately collected in a separate group of rats 1, 2 and 
3 days after pulmonary or oral delivery (see supplementary information). While 80% of the 
dose was excreted in the faeces 1 day after oral dosing, only 9% of the dose was excreted in 
the faeces 1 day after pulmonary dosing. 
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After inhaled delivery, the proportion of the 
3
H dose remaining in the BALF for both 
dendrimers diminished rapidly within the first 3 days, such that after 3 days, less than 5% of 
the delivered dose remained. The proportion of the dose in the lung tissue, however, 
concurrently increased over 3 days, reaching approx. 40% of the nominal dose for both 
dendrimers. This suggested that a significant degree of cellular uptake or tissue penetration of 
the dendrimers occurred over time, although they still displayed limited systemic absorption. 
By day 14, less than 1% of the administered dose remained in the BALF, but a significantly 
larger proportion of the dose was recovered in the lung tissues (Figure 4A).  
Notably, the more hydrophobic MTX dendrimer was cleared more rapidly from the lung 
tissue than the PEG dendrimer over 14 days, such that approx. 5% of the administered dose 
of MTX dendrimer remained in the lung tissue after 14 days compared to approx. 25% of the 
PEG dendrimer. This suggested that replacement of 50% of surface PEG groups with 
hydrophobic drug accelerates lung clearance. This could not be explained solely by increases 
in polylysine scaffold catabolism in the lungs and clearance of low molecular weight 
3
H-
labelled fragments.   
The identify of 
3
H-labelled species in lung tissue homogenate supernatant was also evaluated 
by SEC since levels of 
3
H in the collected BALF were too low to evaluate. The SEC profiles 
showed that the major 
3
H labelled species present in the lungs after administration of the PEG 
dendrimer corresponded to the intact construct over 14 days (Figure 5C). In comparison, the 
SEC profiles of lungs from rats delivered the MTX dendrimer showed increasing amounts of 
low molecular weight fragments over time (Figure 5F). Interestingly, incubation of the PEG 
dendrimer with fresh lung tissue homogenate for 24 h at 37°C did not alter the SEC profile 
when compared to the dendrimer in mobile phase alone (Figure 5B). In contrast, incubation 
of the MTX dendrimer with lung tissue homogenate resulted in ‘peak splitting’ and the 
elution of a slightly lower molecular weight product that corresponded to the major high 
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molecular weight peak in lung tissue samples collected from MTX dendrimer dosed rats 
(Figure 5E). This suggests that the more hydrophobic dendrimer displayed increased 
sensitivity to catabolism by lung-resident enzymes than the PEG dendrimer. This was likely a 
result of reduced steric shielding of the polylysine scaffold from enzymes in the lungs due to 
the reduced density of the PEG layer as we have shown previously[9, 11, 21].  
3.4 Biodistribution of inhaled dendrimers 
Patterns of organ biodistribution and excretion via the faeces for both dendrimers were also 
examined after IV and pulmonary administration after 7 days (with the exception of the MTX 
dendrimer after IV administration which was previously analysed and reported at 5 days) 
(Figure 6) [8]. After IV administration, the PEG dendrimer displayed significantly higher 
retention in the liver and spleen compared to the MTX dendrimer, which was consistent with 
evidence of higher elimination of the MTX dendrimer via the urine (Figure 6B). This was 
also consistent with observations after pulmonary administration, with the exception of much 
lower levels of organ biodistribution (less than 5% in liver). The proportion of the lung 
administered MTX dendrimer dose recovered in faeces was also approximately two fold 
higher (approx. 30%) than the PEG dendrimer (approx. 17%), although this was not 
statistically significant (Figure 6A). This does however, suggest a trend towards higher 
mucociliary clearance (of up to 30% of the nominal dose) for the more hydrophobic MTX 
dendrimer than the PEG dendrimer. This data should also be viewed with the caveat that 
approximately 50% of the nominal dose was likely to have been expired during aerosol 
delivery, suggesting that up to 60% of the lung-delivered dose of the MTX dendrimer was 
cleared via the mucociliary escalator.  
3.5 Evaluation of immune cell populations and levels of pro-inflammatory cytokines in 
the lungs after aerosol administration of dendrimers  
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The total number of cells in the BALF of different groups of rats were determined using a 
Tali® image-based cytometer (Figure 7A). Intratracheal delivery of LPS significantly 
increased the alveolar cell population within 4 h. Specifically, LPS (positive control for lung 
inflammation) increased cell numbers in the BALF by approx. 100 fold compared to the 
delivery of saline (negative control for lung inflammation) after 7 days (P<0.05). Seven days 
after lung administration of the PEG and MTX dendrimers, total cell counts in the BALF did 
not differ significantly to the saline control group, but were significantly lower compared to 
the LPS dosed rats. FACS analysis was then used to determine whether individual 
populations of alveolar macrophages, neutrophils and T-lymphocytes in the BALF were 
altered after pulmonary delivery of the dendrimers, despite the lack of overall change in total 
cell numbers (Figure 7B-D).  
The individual populations of alveolar macrophages, neutrophils and T-lymphocytes in the 
BALF were respectively 10, 800 and 600 fold higher in LPS treated rats compared to saline 
dosed rats. While the number of alveolar macrophages, neutrophils and T-lymphocytes in the 
BALF appeared to be higher 7 and 14 days after pulmonary administration of the PEG 
dendrimer, and 3 days after administration of the MTX dendrimer compared to saline control 
rats, these were not significantly elevated. For the PEG dendrimer, the highest alveolar 
macrophage count was observed on day 7, but neutrophil and T-lymphocyte counts appeared 
to steadily increase until day 14. For the MTX dendrimer however, alveolar macrophage and 
neutrophil counts were only transiently, and not significantly, elevated on day 3 and returned 
to similar levels to saline dosed rats by day 7. In general therefore, there appeared to be a 
trend towards higher macrophage, neutrophil and T-lymphocyte counts for the fully 
PEGylated dendrimer that displays more prolonged lung retention compared to the partially 
drugylated dendrimer, although these differences were not statistically significant. 
SENTENCE REMOVED. 
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The concentrations of TNFα, IL-1β and MCP-1 in the BALF (cell free supernatants) of rats 
dosed with LPS, saline and the dendrimers were also evaluated to further evaluate whether 
the delivery of dendrimers to the lungs induced localised inflammation (Figure 8). 
Administration of LPS resulted in significant increases in all cytokine levels by 12, 34 and 5-
fold respectively compared to saline vehicle control rats (P<0.05). In contrast, the inhaled 
administration of PEG and MTX dendrimers did not result in changes to the levels of these 
inflammatory cytokines in the lungs at the time points evaluated. 
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4. DISCUSSION 
PEGylated polylysine dendrimers have shown considerable potential for the development of 
next generation inhalable nanomedicines. One of the most important properties of the 
polylysine dendrimer delivery system, and one that make it an attractive inhalable drug 
delivery platform, is its capacity for biodegradation [20]. A large body of work has shown 
that polylysine dendrimers degrade after the liberation of surface conjugated drugs and are 
either rapidly cleared as low molecular weight dendrimer fragments in urine or are 
incorporated into protein resynthesis pathways via utilisation of liberated monomeric L-lysine 
[7, 9, 11, 22]. The pulmonary pharmacokinetic properties of polylysine dendrimers can also 
be modulated by altering the size of surface conjugated PEG moeities to facilitate both local 
and systemic delivery [11, 20]. To this point, however, the impact of hydrophobic drug 
conjugation on the fate of inhaled polylysine dendrimers has not been specifically evaluated. 
This is important since hydrophobic drug loading is expected to significantly change the 
physicochemical properties of PEGylated dendrimers such that pulmonary pharmacokinetic 
predictions based on size and PEG loading alone will be inaccurate. We therefore 
hypothesised that the partial substitution of surface PEG groups with hydrophobic drug will 
change the kinetics and pathways of dendrimer clearance from the lungs. The hypothesis was 
tested by comparing the pulmonary pharmacokinetics of a fully PEGylated polylysine 
dendrimer to an identical construct where 50% of the surface PEG groups were replaced with 
the model hydrophobic drug OtBu-methotrexate after inhaled administration in rats. It is 
important to note at this point however, that pharmacokinetic parameters and biodistribution 
were calculated based on the ‘nominal’ pulmonary delivered dose. Pharmacokinetic data 
therefore needs to be evaluated with the caveat that biodistribution values after inhaled 
administration can in fact be up to twice as high as those reported here on the basis that half 
of the delivered dose was cleared from the lungs during or immediately after dosing. 
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In the present study, both dendrimers showed limited systemic absorption (within 3% over 7 
days) due to their high molecular weights. The low bioavailability after pulmonary 
administration is in agreement with previous reports which suggest that the rate and extent of 
absorption of inhaled PEGylated polylysine dendrimers and other macromolecules from the 
lungs is inversely proportional to molecular mass [5, 11, 23]. This is a result of the very tight 
junctions between alveolar epithelial cells that limit the paracellular transport of 
macromolecules. The more hydrophobic MTX dendrimer did, however, appear to display 
approx. 2-fold higher pulmonary bioavailability compared to the fully PEGylated construct. 
In addition, a larger proportion of the MTX dendrimer dose was cleared via the urine as low 
molecular weight products of polylysine catabolism compared to the PEG dendrimer. 
Interestingly, while pulmonary bioavailability was quite low, urinary elimination of both 
dendrimers after inhaled administration was approx. half of that after IV administration, 
suggesting more efficient scaffold metabolism in the lungs than systemically. This was 
supported by SEC profiles of lung tissue homogenate supernatant that showed increasing 
proportions of low molecular weight 
3
H-labelled products from both dendrimers in the lungs 
over time. This data suggests that drug conjugation, and the resulting increase in 
hydrophobicity, of a PEGylated dendrimer enhances lung clearance via both biodegradation 
and absorption into systemic circulation. This is consistent with the results of previous studies 
that have shown that reducing the degree of PEGylation on polylysine dendrimers better 
exposes the dendrimer scaffold to proteolytic enzymes and reduces in vivo stability [20, 24]. 
Mucociliary clearance, however, was the dominant lung clearance mechanism for both 
dendrimers, which is consistent with our previous work showing that this is the major lung 
clearance pathway for high molecular weight PEGylated polylysine dendrimers [11]. Notably 
though, the proportion of the pulmonary dose recovered in faeces after delivery of the MTX 
dendrimer (approx. 32%) was twice as high as the PEG dendrimer (approx. 16%) suggesting 
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that the more hydrophobic surface enhanced mucociliary expulsion. These results are in 
agreement with studies that have shown that particles with hydrophilic and neutral surfaces 
have better mucus penetrating properties and capacity to reach the lung epithelium (and 
access to the lung tissue) than particles with hydrophobic surfaces which form stable 
polyvalent bonds with mucin, facilitating entrapment in mucus and clearance via the 
mucociliary escalator [6, 12]. Previous work has also shown that by coating the surface of 
hydrophobic nanoparticles with low molecular weight PEG, the resulting increase in surface 
hydrophilicity and reduction in overall surface charge minimizes hydrophobic adhesive 
interactions with mucus and reduces mucociliary expulsion [12, 25]. 
Consistent with pharmacokinetic data showing more efficient lung clearance of the MTX 
dendrimer via absorption, metabolism and mucociliary elimination compared to the PEG 
dendrimer, lung retention data over 14 days similarly showed that the MTX dendrimer was 
cleared more rapidly than the PEG dendrimer (4 vs 25% dose remaining in the lungs after 14 
days respectively). Lung retention of both the PEG and MTX dendrimers was similar until 3 
days after inhaled delivery, but beyond this, the patterns of dendrimer retention diverged 
dramatically, such that lung levels of the PEG dendrimer decreased by only 10% from day 3 
to day 14. This was in contrast to the levels of MTX dendrimer in the lungs which continued 
to decrease over the next 2 weeks. Beyond the immediate post-dose period, most of the lung-
resident dendrimer was associated with the lung tissue, suggesting access to the lung 
parenchyma without significant absorption. While unusual for a macromolecular species, this 
is consistent with previous observations with other PEGylated dendrimers [11]. To provide a 
better understanding of why the MTX dendrimer displayed more accelerated lung clearance 
than the PEG dendrimer, the size of 
3
H-labelled species in the lung tissue was examined via 
SEC. The SEC profiles appeared to suggest higher in vivo stability of the inhaled PEG 
dendrimer in the lung tissues than the MTX dendrimer, with profiles showing that a greater 
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proportion of 
3
H in the lung tissues of MTX dendrimer dosed rats was associated with low 
molecular weight fragments compared to the PEG dendrimer which showed a greater 
proportion of intact dendrimer. This appears to suggest that the 50% drugylated and 50% 
PEGylated dendrimer was considerably more susceptible to biodegradation in the lung tissues 
than the fully PEGylated construct, and this is supported by the SEC profiles at 3 days (when 
the proportion of the dose of MTX and PEG dendrimers remaining in the lungs was 
identical). However, the more rapid lung clearance of the MTX system (presumably via 
mucociliary expulsion) beyond 3 days compared to the PEG system may have primarily led 
to the clearance of intact dendrimer, leaving behind surface 
3
H-labelled fragments containing 
PEG and MTX. Never the less, SEC profiles suggest more prolonged retention of the fully 
PEGylated construct in lung tissues and more rapid elimination of the intact MTX construct 
from the lungs over 14 days.  
The inhaled delivery of some nanomaterials can also promote localised inflammatory 
reactions which might be expected to have a marked effect on the clearance of delivered 
nanomaterials. For instance, several studies have shown that nanoparticles, (to this point 
mostly non-biodegradable and inorganic nanoparticles) mediate pulmonary inflammation that 
is characterized by an increase in the number of alveolar macrophages, neutrophils, T-
lymphocytes and eosinophils in the bronchoalveolar space and lung tissues, and enhanced 
expression of pro-inflammatory cytokines and chemokines, such as TNF-α, IL-1β, MCP-1, 
MIP-1α and MIP-2 [26-28]. The significance of this is that lung inflammation has been 
reported to increase the systemic absorption of inhaled nanoparticles by compromising the 
integrity of the alveolar epithelium [15]. In this study, any differences in the ability of the two 
dendrimers to stimulate lung inflammation after inhaled delivery was therefore expected to 
compromise the ability to evaluate how changes in their physicochemical properties changed 
lung clearance kinetics and pathways. For instance, several studies have indicated that 
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hydrophobic particles (hydrophobic interaction chromatography [HIC] index > 0.8) are 
implicated in the inflammatory foreign body response or are recognized by the immune 
system as a ‘damage-associated molecular pattern’, whilst less hydrophobic systems are not 
[29-33]. We therefore evaluated whether either of the dendrimers examined here induced any 
inflammatory effects in the lungs. 
In the current study, transient increases in several immune cells into the lungs appeared to be 
present after inhaled administration of both dendrimers, and these increases appeared to 
reflect the lung residence of the dendrimers. For instance, neutrophil counts increased over 14 
days after administration of the PEG dendrimer which showed prolonged lung retention, 
while neutrophil counts peaked 3 days after lung administration of the MTX dendrimer, but 
rapidly declined as the dendrimer was cleared from the lungs. However, these elevations in 
cell number were not statistically significant compared to saline vehicle dosed rats. This is 
consistent with the presence of a mild and reversible adaptive physiological response in the 
lungs, which normally occurs after the inhaled exposure of the lungs to any nanosized 
material [34] [35]. Further, no significant changes in the level of pro-inflammatory cytokines 
TNFα, IL-1β or MCP-1 were evident in the BALF, suggesting that neither dendrimer induced 
significant lung inflammation after a single 5 mg/kg inhaled dose. These results are consistent 
with a previous study that showed that the cumulative lung administration of up to 80 mg 
partly PEGylated dendrimer to rats had little impact on the lung tissue, with mild increases in 
macrophages and alveolar fluid reported in only 50% of the rats examined [9]. Further, recent 
in vitro and in vivo studies have reported that biodegradable nanosized drug delivery systems 
are innocuous towards lungs, and show no significant ‘inflammatory response’ (elevated 
cytokines together with BALF immune cell populations and BALF protein content) 
compared to vehicle controls [36, 37].   
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5. CONCLUSION 
The results of this study showed that substitution of 50% of the surface PEG groups on a 
fully PEGylated polylysine dendrimer with a model hydrophobic drug accelerated its lung 
clearance via a combination of increased dendrimer biodegradation, absorption of intact 
dendrimer and low molecular weight products of polylysine scaffold catabolism, plus 
mucociliary clearance. These differences in lung clearance kinetics occurred without 
pronounced lung inflammation, suggesting that more hydrophobic nanomedicines are likely 
to be cleared from the lungs more readily than highly hydrophilic systems. This has important 
implications in the design of inhalable polymer-based nanomedicines such as dendrimers, 
where drugs may be conjugated to the surface of the nanomedicine. Thus, whilst more 
hydrophilic systems promote better solubility in liquid aerosol solutions and in the lungs, 
more hydrophobic systems are likely to be cleared more readily from the lungs and are 
therefore expected to be safer for long term use. 
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Tables: 
 
Table 1. Pharmacokinetic parameters for dendrimers after IV or inhaled delivery of 5 mg/kg 
dendrimer construct to rats. 
 PEG dendrimer MTX dendrimer 
 Pulmonary IV Pulmonary IV
#
 
T½
 
(h)  65 ± 18 88 ± 17* ND 32 ± 2 
AUC0-∞ (µg/ml.h)  96 ± 26 3998 ± 567* ND 2734 ± 161 
AUC0-7d (µg/ml.h)  69  ± 20 ND 83 ± 13 ND 
C
max 
(µg/ml)  0.5 ± 0.0 85 ± 5 0.8 ± 0.2 86 ± 6 
T
max
 (h) 54 ± 39  - 102 ± 36  - 
Clearance (ml/h) - 0.4 ± 0.0 - 0.5 ± 0.0 
VDβ (ml) - 44 ± 4* - 22 ± 3 
Vc (ml) - 17 ± 1 - 15 ± 1 
Fabs
0-∞
 (%) 2.4 ± 0.7 - ND - 
Fabs
0-7d
 (%) 1.7 ± 0.5 - 3.0 ± 0.5 - 
% of dose in urine  1.7 ± 1.0* 3.7 ± 0.8* 6.8 ± 3.0 13.6 ± 1.5 
*Represents p < 0.05 compared to the equivalent parameter for MTX. Data represent mean ± 
SD (n = 3-4 rats). ND – not determined. # reproduced from [8]. 
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Figures: 
 
                         
Figure 1: Structure of a generation 5 PEGylated polylysine dendrimer conjugated with 
PEG1100 at all surface ε amino groups and PEG1100 (PEG dendrimer) or α-carboxyl OtBu-
methotrexate linked via a hexapeptide (PVGLIG) linker (MTX dendrimer) on surface α-
amino acid groups. (*) represents the point of attachment to surface amino groups (X) on the 
polylysine scaffold. 
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Figure 2. Plasma concentration-time profiles of the PEG and MTX dendrimers after IV or 
pulmonary dosing of 5 mg/kg to rats.  Data for IV MTX dendrimer is reproduced from[8]. 
Values represent mean ± SD (n = 3-4 rats). 
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Figure 3. Size exclusion chromatography profiles of (A) PEG dendrimer in mobile phase, 
(B) MTX dendrimer in mobile phase, (C) urine collected from rats administered the PEG 
dendrimer via the lungs, (D) urine collected from rats administered the MTX dendrimer via 
the lungs.  
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Figure 4. (A) Proportion of the administered pulmonary dose of both MTX and PEG 
dendrimers recovered in the BALF and lung tissue at each time point; (B) collective 
proportion of the pulmonary dose of PEG dendrimer recovered in the lungs and BALF; (C) 
collective proportion of the pulmonary dose of MTX dendrimer recovered in the lungs and 
BALF. *represents p < 0.05 cf. PEG dendrimer (Lungs). Data are represented as mean ± SD 
(n= 3-4)  
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Figure 5. Size exclusion chromatography of 
3
H-labelled PEG and MTX dendrimers in 
mobile phase (Panels A and D respectively) and after incubation in fresh lung tissue 
homogenates at 37°C for 24 h (Panels B and E respectively). Size exclusion chromatography 
of lung tissue homogenate supernatant from rats delivered aerosol doses of PEG and MTX 
dendrimers (Panels C and F respectively). 
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Figure 6. Biodistribution of 
3
H PEG dendrimer (Grey bars) and MTX dendrimer (White 
bars) following (A) pulmonary and (B) IV dosing. *represents p < 0.05 cf. PEG dendrimer.  
Values represent mean ± SD (n = 3-4 rats). ND – not determined. 
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Figure 7. Differential cell counts in the BALF of rats administered LPS, Saline (Sal), PEG 
dendrimer or MTX dendrimer over 14 days. (A) Total cell count; (B) total macrophage 
population; (C) total neutrophil population; and (D) total T-lymphocyte population. BALF of 
rats administered LPS or saline were collected after 4 h and 7 days, respectively. Values 
represent mean ± SD (n = 3-4 rats). *represents p < 0.05 cf.  all other groups.  
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Figure 8. Levels of TNFα, IL-1β and MCP-1 in the BALF of rats dosed via the lungs with 
LPS, saline (Sal), PEG dendrimer or MTX dendrimer. BALF of rats administered LPS or 
saline were collected after 4 h and 7 days, respectively. Values represent mean ± SD (n = 3-4 
rats). *represents p < 0.05 cf. all other groups for each cytokine. 
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